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Conclusions Patients with isolated in-breast or regional 
breast cancer recurrences should be treated with curative 
intent. Mastectomy is the standard of care for patients with 
ipsilateral breast tumor recurrence. In a subset of patients, 
a second breast conservation followed by partial breast ir-
radiation (PBI) is an appropriate alternative to mastectomy. 
If a second breast conservation is performed, additional irra-
diation should be mandatory. The largest reirradiation expe-
rience base exists for multicatheter brachytherapy; however, 
prospective clinical trials are needed to clearly define selec-
tion criteria, long-term local control, and toxicity.
Following primary mastectomy, patients with resectable 
locoregional breast cancer recurrences should receive mul-
timodality therapy including systemic therapy, surgery, and 
radiation +/− hyperthermia. This approach results in high 
local control rates and long-term survival is achieved in a 
subset of patients. In radiation-naive patients with unresect-
able locoregional recurrences, radiation therapy is mandatory. 
In previously irradiated patients with a high risk of a second 
local recurrence after surgical resection or in patients with 
unresectable recurrences, reirradiation should be strongly 
considered. Indication and dose concepts depend on the time 
interval to first radiotherapy, presence of late radiation effects, 
and concurrent or sequential systemic treatment. Combina-
tion with hyperthermia can further improve tumor control.
In patients with isolated axillary or supraclavicular 
recurrence, durable disease control is best achieved with 
multimodality therapy including surgery and radiotherapy. 
Radiation therapy significantly improves local control and 
should be applied whenever feasible.
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Abstract
Objective To update the practical guidelines for radiother-
apy of patients with locoregional breast cancer recurrences 
based on the current German interdisciplinary S3 guidelines 
2012.
Methods A comprehensive survey of the literature using 
the search phrases “locoregional breast cancer recurrence”, 
“chest wall recurrence”, “local recurrence”, “regional recur-
rence”, and “breast cancer” was performed, using the limits 
“clinical trials”, “randomized trials”, “meta-analysis”, “sys-
tematic review”, and “guidelines”.
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Schlüsselwörter Brustwandrezidiv Mammakarzinom · 
Axilläres Rezidiv Mammakarzinom ·  
Supraklavikuläres Rezidiv Mammakarzinom · 
Mastektomie · Rebestrahlung
Introduction
Treatment of locally recurrent breast cancer remains an inter-
disciplinary challenge, since treatment options are limited 
or at least restricted due to previous treatments. Data from 
large randomized trials have demonstrated that locoregional 
recurrences occur in approximately 5–15 % of patients, 
despite them having received adjuvant radiotherapy after 
primary mastectomy or breast-conserving surgery (BCS; 
[1–4]). The most common site of recurrence after adjuvant 
radiotherapy is the ipsilateral breast or chest wall, compris-
ing 60–95 % of all locoregional events [5–7]. Locoregional 
recurrences are typically associated with an increased risk 
of concurrent or subsequent systemic relapses [8, 9]. Partic-
ularly early recurrences within the first 2 years after primary 
treatment seem to have a worse prognosis [9]. As previous 
guidelines from the German Society of Radiation Oncology 
(DEGRO) expert panel [10–12] focused on primary treat-
ment of breast cancer, the current publication addresses 
radiotherapeutic options for locoregional recurrences.
Therapy of ipsilateral breast tumor recurrence
Statement of theGerman S3 Guidelines 2012 [13]:
Statement recurrence 1: Local (in-breast) recurrence
a. In patients with invasive or noninvasive in-breast recur-
rences, optimal local tumor control is achieved with a 
secondary mastectomy.
b. In patients with ductal carcinoma in situ or invasive 
breast cancer with a long recurrence-free interval and 
no skin infiltration, a second breast conservation can be 
considered.
c. In the case of a second breast conservation, the pos-
sibility of reirradiation (partial breast irradiation, PBI) 
should be evaluated.
d. In the case of a second breast conservation, the patient 
should be informed about an increased risk of subse-
quent in-breast recurrence.
BCS followed by adjuvant radiotherapy has become the 
standard of care for the majority of breast cancer patients. 
Ipsilateral breast tumor recurrence (IBTR) is diagnosed in 
approximately 5–10 % of patients at 10 years after breast-
conserving therapy (BCT; [10, 14–17]). International 
guidelines recommend mastectomy as standard treatment 
for IBTR after BCT [13, 18]. Salvage mastectomy results 
DEGRO-Leitlinien für die Strahlentherapie des 
Mammakarzinoms VI: Therapie lokoregionaler 
Mammakarzinomrezidive
Zusammenfassung
Ziel Aktualisierung der Strahlentherapieleitlinien bei Pati-
enten mit lokoregionalen Mammakarzinomrezidiven, basie-
rend auf der aktuellen S3-Leitlinie.
Methoden Es erfolgte eine umfassende Recherche der wis-
senschaftlichen Literatur mit den Suchbegriffen: „lokore-
gionales Mammakarzinomrezidiv“, „Thoraxwandrezidiv“, 
„Lokalrezidiv“, „regionales Rezidiv“ und „Mammakarzi-
nom“, eingeschränkt durch die Begriffe „klinische Studie“, 
„randomisierte Studie“, „Metaanalyse“, „systematischer 
Review“ und „Leitlinie“.
Schlussfolgerungen Patienten mit isolierten In-Brust- oder 
regionalen Rezidiven sollten mit kurativer Intention behan-
delt werden. Bei Patienten mit einem ipsilateralen In-Brust-
Rezidiv ist eine Mastektomie die Standardbehandlung. Bei 
einem Teil der Patienten ist eine erneute Brusterhaltung mit 
anschließender Teilbrustbestrahlung eine angemessene Al-
ternative zur Mastektomie. Nach erneuter Brusterhaltung 
sollte eine Bestrahlung obligat durchgeführt werden. Die 
größten Erfahrungen zur Rebestrahlung existieren für die 
Multikatheter-Brachytherapie. Dennoch sind prospektive 
Studien notwendig, um Selektionskriterien sowie Langzeit-
toxizität und -kontrollraten genauer zu bestimmen.
Patienten mit resektablen lokoregionalen Mammakarzi-
nomrezidiven nach primärer Mastektomie sollten mit einem 
multimodalen Therapiekonzept mit kompletter Resek-
tion, systemischer Therapie und Bestrahlung +/− Hyper-
thermie behandelt werden. Hierdurch können hohe lokale 
Kontrollraten und in einem Teil der Patienten lange Über-
lebenszeiten erreicht werden. Eine Strahlentherapie sollte 
obligat bei bisher nicht bestrahlten Patienten mit inopera-
blen lokoregionalen Rezidiven durchgeführt werden. Bei 
vorbestrahlten Patienten mit einem hohen Rezidivrisiko 
nach chirurgischer Resektion oder einem inoperablen 
Rezidiv sollte eine Rebestrahlung dringend in Erwägung 
gezogen werden. Indikationsstellung und Dosiskonzepte 
sind vom Intervall zur ersten Bestrahlung, der Präsenz und 
dem Ausmaß später Strahlenreaktionen sowie von paral-
lelen/sequenziellen systemischen Therapien abhängig. Eine 
Kombination mit einer zusätzlichen Hyperthermie kann die 
Tumorkontrolle weiter verbessern.
Bei Patienten mit isolierten axillären oder supraklavi-
kulären Rezidiven kann eine dauerhafte Krankheitskontrolle 
am besten mit einem multimodalen Behandlungskonzept 
bestehend aus Chirurgie und Radiotherapie erreicht werden. 
Eine Strahlentherapie sollte, wann immer möglich, durch-
geführt werden, da sie zu einer signifikanten Verbesserung 
der lokalen Kontrolle führt.
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conservative surgery followed by partial-breast irradiation 
(PBI; [34, 35]). The following survey provides an overview 
of different radiation techniques applied for reirradiation 
after BCS for IBTR (Table 3).
Brachytherapy after BCS for IBTR
The most solid evidence for reirradiation of IBTR exists for 
brachytherapy (BT). The Groupe Européen de Curiethéra-
pie and the European Society for Radiotherapy & Oncology 
(GEC-ESTRO) working group reported on a retrospec-
tive collaborative analysis of 217 IBRT patients treated 
between 2000 and 2009 with multicatheter BT in eight 
European institutions [35]. The median total doses delivered 
through low dose rate (LDR) and pulsed dose rate (PDR) 
BT were 46 Gy (range 30–55 Gy) and 50.4 Gy (range 
49–50 Gy), respectively, and 32 Gy (range 22–36 Gy; 
equivalent dose in 2-Gy fractions: 43 Gy4) in 5–10 fractions 
(median 8 fractions) fractions (twice daily) for high dose 
rate (HDR) BT. With a median follow-up of 3.9 years (1.1–
10.3 years) after IBTR retreatment, the 5- and 10-year actu-
arial second local recurrence rates were 5.6 % (1.5–9.5 %) 
and 7.2 % (2.1–12.1 %), respectively. The grade 3 and 4 
in locoregional control rates of 69–98 % and 5-year sur-
vival rates of 53–85 % [19, 20]. Nevertheless, this approach 
is not founded on solid data demonstrating a clear advan-
tage of radical surgery over a second attempt at BCT for 
all IBTR patients [21]. There are no published or ongoing 
prospective studies comparing mastectomy to repeat BCS 
in patients with IBTR. Published data are limited and most 
series reporting on a second conservative approach, with or 
without the addition of adjuvant radiotherapy, are single-
institution retrospective studies. The Radiation Therapy 
Oncology Group (RTOG) introduced a phase II prospec-
tive trial of repeat BCS adding 3D conformal partial breast 
reirradiation for local recurrence in 2010 [22]. Additionally, 
mutilating rescue surgery causes patients enormous emo-
tional and physical distress [23]. Furthermore, the currently 
implemented close follow-up routine has led to detection 
of IBTR at early stages technically amenable to a second 
breast conserving approach. Thus, a subgroup of patients 
remains to be defined who can be safely treated with a sec-
ond breast conserving approach without oncologic com-
promises. Unfortunately, no prospective data have been 
published so far.
Definition of selection criteria for a second BCS
Veronesi et al. suggested that patients with IBTR consti-
tute a heterogeneous group, with true tumor recurrences 
and new primary tumors [24]. In a large retrospective study 
on 1410 patients, Gujral et al. [25] reported a cumulative 
incidence rate of new primaries after whole-breast irradi-
ation of 0.8, 2, and 3.5 % at 5, 10, and 15 years respec-
tively. The authors concluded that whole-breast irradiation 
approximately halves the rate of new primaries. Smith et al. 
[26] reported a significantly improved 10-year overall sur-
vival (OS) in patients with new primaries (75 %) compared 
to patients with true recurrences (55 %) in a retrospective 
study on 136 patients with IBTR as the first site of failure. 
This question has been addressed in several studies attempt-
ing to differentiate between true recurrences and new prima-
ries [26–29], from which the following conclusions can be 
derived: the majority of IBTR are true recurrences, which 
tend to occur earlier and in the same quadrant as the initial 
tumor, metastasize earlier and more often, and have a shorter 
overall and disease-free survival (DFS) than new prima-
ries. Further retrospective studies [30–32] evaluating IBTR 
showed that there are subgroups of patients with improved 
rates of OS, DFS, and second local recurrence. Based on 
these data, the DEGRO expert panel suggests possible selec-
tion criteria for patients who may be candidates for a second 
breast-conserving approach (Table 1). However, repeat BCS 
alone is associated with increased local failure rates ranging 
between 19 and 38 % (Table 2; [33]). Recent studies showed 
promising OS rates in selected patients treated with second 
Table 2 Outcomes of patients treated with repeat breast conserving 
surgery alone following ipsilateral breast tumor recurrence













Kurtz [43] 1989 55 51 32 NR
Abner [44] 1993 16 39 31 81
Salvadori [45] 
1999
57 73 19 85
Voogd [46] 1999 16 52 38 NR
Ishitobi [47] 2011 78 40 21 NR
Gentilini [48] 
2012
161 81 29 84
NR not reported
Table 1 Possible selection criteria for patients with ipsilateral breast 
tumor recurrence who may be candidates for a second breast-conserv-
ing approach
Isolated ipsilateral breast tumor recurrence
Limited size (< 2–3 cm)
Unifocal disease on ultrasound, mammography, and MRI
Age ≥ 50 years
Long interval between primary treatment and recurrence 
(≥ 48 months)
Patient preference for a second breast conservation followed by 
radiotherapy
A second breast conservation is technically feasible and will result 
in acceptable cosmetic results
The DEGRO expert panel suggests the following selection 
criteria for a second breast conserving approach
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Toxicity assessment/cosmetic outcome of repeat 
irradiation for IBTR
In all publications, acute toxicities of the respective method 
were reported to be low, while the most frequent late reac-
tion pattern was fibrosis. Particularly when assessed by stan-
dardized scoring systems, grade 1–2 sequelae in terms of 
fibrosis, telangiectasia, and/or pain ranged between 44 and 
79 % [35, 37, 42]. Severe late reactions, such as skin necrosis 
or ulceration, were hardly ever stated. In the GEC-ESTRO 
series of 217 patients [35], 141 patients (65 %) developed 
late effects: cutaneous and subcutaneous fibrosis (67 %), tel-
angiectasia (16 %), hyperpigmentation (9 %), and ulceration 
(1 %). Grade 3 and 4 complications were reported in 10and 
1 %, respectively. The cosmetic results were assessed in 
109 patients (50.2 %) and rated excellent in 52 (48 %), good 
in 40 (37 %), fair in 14 (13 %), and poor in 2 (2 %) patients.
Conclusions of the DEGRO expert panel for the therapy of 
ipsilateral breast cancer recurrences
 ● Although mastectomy is regarded as the standard of care 
for patients with IBRT, in a subset of patients, PBI after 
second BCS is an appropriate alternative to mastectomy 
(Table 1).
 ● This approach yields high breast preservation rates and 
does not seem to compromise oncologic safety.
 ● If a second breast conservation is performed, additional 
irradiation should be mandatory, particularly in patients 
who have not received previous irradiation.
 ● In the case of reirradiation, the largest experience base to 
date exists for multicatheter BT.
 ● There is only limited information about the effectiveness 
of EBRT or IORT, which should be preferentially per-
formed in clinical trials.
 ● Prospective studies are needed to clearly define selection 
criteria, long-term local control, and toxicity.
complication rates were 10 % and 1 % (ulceration), respec-
tively. Excellent or good cosmetic results were achieved 
in 85 %. Further endpoints were the evaluation of survival 
rates without second IBTR, as well as metastatic recurrence, 
DFS, and OS. In comparison to salvage mastectomy series, 
results were reported to be at least equivalent, with 5- and 
10-year actuarial rates for metastatic recurrence of 9.6 % 
and 19.1 %, DFS of 84.6 % and 77.2 %, and OS of 88.7 % 
and 76.4 %, respectively. Further single-institution studies 
with small patient numbers support these data [36–39].
External beam radiotherapy after BCS for IBTR
There is a single report on external beam radiotherapy 
(EBRT) for treatment of IBTR [40] comprising 39 patients. 
Retreatment was performed using electrons in single frac-
tional doses of 2 Gy up to 50 Gy to the involved quadrant. 
At a median follow-up of 51.5 months, 30 women (76.9 %) 
had an intact breast free of tumor. The RTOG initiated a 
phase II study of repeat breast-preserving surgery and 
3D conformal partial breast reirradiation (PBI) for local 
recurrence of breast carcinoma with single doses of 1.5 Gy 
in 15 fractions, twice daily, to a total dose of 45 Gy [22]. 
The study has reached the accrual goal of 61 patients and is 
closed, but not yet published.
Intraoperative radiotherapy after BCS for IBTR
There is only one publication considering intraoperative 
radiotherapy (IORT) for reirradiation of IBRT [41]. A total 
of 15 patients were treated by applying IORT with 50-kV 
X-rays in single dosages of 14.7–20 Gy (applicator surface). 
At a medium follow-up of 26 months (1–60 months), no 
local recurrences occurred.
Table 3 Outcomes of patients treated with repeat breast conserving surgery and radiotherapy following ipsilateral breast tumor recurrence












Deutsch [40] 2002 39 51.5 EBRT 50 NR 77 78
Kraus [41] 2007 15 26 IORT 20 0 100 93
Chada [38] 2008 15 36 BT 30 or 45 0 89 100
Guix [42] 2010 36 89 BT 30 0 89a 97a
Kauer [37] 2012 39 57 BT 50 17b/0 93 87




NR not reported, RT radiation therapy, EBRT external beam radiotherapy, IORT intraoperative radiotherapy, LDR low dose rate, PDR pulsed 
dose rate, HDR high dose rate
a10-year actuarial
b4 % breast tissue fibrosis and 13 % subjective breast pain
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treatment group were treated to a dose of 50 Gy plus a boost 
of 10 Gy, while the dose escalation group was treated to a 
dose of 54 Gy plus a 12-Gy boost. The authors observed a 
77 % locoregional control rate (LCR) and a 55 % OS rate at 
5 years for the entire group. OS and LCR were not signifi-
cantly improved in the dose escalation group. In summary, 
patients with an isolated locoregional recurrence after mas-
tectomy should undergo surgical resection. Postoperative 
radiation therapy to the chest wall is mandatory and regional 
nodal irradiation is strongly advised [18, 58]. A standard dose 
of 50–50.4 Gy with 1.8-/2-Gy fractions should be applied. An 
additional boost dose of 10 Gy can be applied, particularly if 
risk factors are present. A further approach to enhance radia-
tion effectiveness is the additional use of hyperthermia. This 
combination improved clinical response and local control in 
several phase II studies and randomized trials [59, 60].
For systemic management, endocrine therapy should be 
administered to all hormone receptor-positive patients in 
addition to local excision and radiotherapy [61]. In a pro-
spective randomized study, Aebi and colleagues [62] inves-
tigated the effects of chemotherapy in 162 patients with 
completely resected isolated locoregional breast cancer 
recurrences. These authors found that adjuvant chemother-
apy in addition to radiation and endocrine therapy prolonged 
DFS and OS, particularly in patients with estrogen receptor-
negative locoregional relapse. The 5-year DFS and OS rates 
were 69 and 88 %, respectively. This result challenges the 
current practice of reluctant use of chemotherapy and pro-
vides evidence in favor of offering adjuvant chemo- and 
radiotherapy to women with completely resected isolated 
locoregional relapse of breast cancer.
Treatment of unresectable recurrences in radiation-
naive patients
In patients with unresectable isolated locoregional recur-
rences who have not previously been irradiated, radiation 
therapy is mandatory. In a retrospective study, Skinner 
et al. [57] reported that patients with gross disease at the 
time of radiation had significantly lower 5-year local con-
trol (63 %) and survival rates (34 %) compared to patients 
with no residual disease after surgery or systemic therapy 
(81 and 62 %, respectively). If complete remission after 
radiation therapy was accomplished, the 5-year survival 
rate increased from 27 to 62 % [57]. Therefore, the same 
recommendations for radiation and endocrine therapy apply 
as for resectable disease. The boost dose can be increased 
depending on the size and location of the recurrence. The 
indication for additional chemotherapy should be defined on 
an individual basis, since no prospective data are available 
[63–65]. In summary, multimodality therapy including sys-
temic and radiation therapy has the potential to cure selected 
patients [9, 53, 66–68].
Treatment of local recurrence after mastectomy
Statements of the German S3 Guidelines 2012 [13]:
Statement recurrence 2: Local recurrence after 
mastectomy
 ● An isolated chest wall recurrence should be completely 
resected (R0).
Statement recurrence 5: Radiotherapy after surgery for 
recurrence
a. The indication for radiotherapy after recurrence surgery 
should be discussed and decided on an interdisciplin-
ary basis. Postoperative irradiation can be applied if no 
previous irradiation was accomplished or in cases of in-
complete resection (R1/R2).
b. In inoperable patients, palliative radiotherapy can be 
reasonable for systemic control.
Definition and patterns of recurrence
A locoregional breast cancer recurrence after mastectomy 
is defined as the appearance of tumor in the ipsilateral chest 
wall, or the axillary, internal mammary, or supraclavicular 
lymph nodes [8]. The Early Breast Cancer Trialists’ Collab-
orative Group analysis revealed a 10-year risk of an isolated 
locoregional recurrence as the first event after mastectomy 
of 20.3 % for patients with 1–3 positive axillary lymph 
nodes, and of 32.1 % for patients with ≥ 4 positive nodes. 
The addition of radiotherapy significantly reduced the risk 
to 3.8 and 13 %, respectively [2, 49, 50]. In cohorts treated 
with modern systemic therapies, the total locoregional 
recurrence rate is substantially lower; however, the relative 
risk reduction after radiotherapy remains unchanged [51]. 
Katz et al. [52] reported on local recurrence patterns in a ret-
rospective study of 1031 women treated in five prospective 
trials with mastectomy and adjuvant chemotherapy without 
radiation therapy. After a median follow-up of 116 months, 
the most common sites of isolated locoregional recurrences 
were the chest wall and the supraclavicular lymph nodes. 
There is evidence that a local recurrence per se is the stron-
gest predictor for a further recurrence [9].
Treatment of resectable recurrences in radiation-naive 
patients
If no previous irradiation has been performed, optimal treat-
ment consists of complete excision of gross disease followed 
by irradiation [8, 53]. This approach improved local control 
[54, 55] and may have an effect on survival [53, 56]. Skinner 
et al. [57] evaluated the effects of dose escalation on local 
control and survival in 159 patients with an isolated locore-
gional recurrence after mastectomy. Patients in the standard 
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tion. Harms et al. [75] reported on a retrospective study in 
58 patients treated with PDR BT molds. The local control 
rate was 79 %. Grade III fibrosis was experienced by 10 % 
of the patients and grade IV late effects were suffered by 
7 %.
An increasing number of studies on the combination of 
hyperthermia and reirradiation of the chest wall have been 
published (Table 4; [59, 60, 71–74, 76, 77]). Jones and col-
leagues [60] enrolled 109 patients with superficial tumors 
(70 patients with breast cancer) in a prospective random-
ized trial comparing irradiation of chest wall recurrences 
with irradiation and additional hyperthermia. The complete 
response rate was 66.1 % in the hyperthermia and 42.3 % in 
the irradiation-only arm. Previously irradiated patients had 
the greatest incremental gain in complete response: 23.5 % 
in the non-hyperthermia versus 68.2 % in the hyperthermia 
arm. No OS benefit was seen. The authors concluded that 
adjuvant hyperthermia resulted in a significant local control 
benefit in patients with superficial tumors receiving radia-
tion therapy. These data are supported by a meta-analysis of 
five randomized trials including 306 patients with advanced 
primary or recurrent breast cancer [59]. The complete remis-
sion rate was significantly improved in patients treated with 
combined radiation and hyperthermia compared to radiation 
alone (59 vs. 41 %). OS was not improved.
More recent data were published in a retrospective analy-
sis of 198 patients who underwent either R0 (n = 107) or R1 
resection (n = 91) for recurrent breast cancer. Hyperthermia 
was used as an adjunct to reirradiation (eight 4-Gy fractions; 
[73]). After a median follow-up of 42 months, the 5-year 
locoregional control rate was 78 %. The 5-year grade III/IV 
Therapy of locoregional recurrences after mastectomy 
in previously irradiated patients
Treatment options are limited in patients with locoregional 
recurrences after mastectomy and adjuvant radiotherapy. 
The optimal sequence of multimodal treatments in this situ-
ation has not been evaluated in prospective trials. In cur-
rent practice, most of these patients are initially treated 
with systemic therapy, in analogy to neoadjuvant systemic 
treatment of primarily unresectable breast cancer. If com-
plete resection is possible, surgery should be accomplished; 
however, “heroic surgery” resulting in large tissue defects 
or prolonged wound healing problems should be avoided. 
Traditionally, reirradiation has been used with caution, in 
fear of an increased normal tissue complication rate. How-
ever, a number of small to intermediate size clinical trials 
have revealed that the grade IV late toxicity after reirradia-
tion with EBRT was within an acceptable range, not exceed-
ing 12 % [5, 69–74]. Simultaneous radiochemotherapy as a 
treatment option has been investigated in a limited number 
of trials [63, 64].
Reirradiation with or without regional hyperthermia
Laramore et al. [69] reported on 13 patients treated with 
conventionally fractionated electrons for chest wall recur-
rences. All patients had received previous postoperative 
chest wall irradiation with doses between 40 and 50 Gy. 
Of these patients, 62 % were alive and free of local disease 
after a median follow-up of 12 months. Skin reactions were 
limited to temporary erythema and dry or moist desquama-
Table 4 Outcomes of patients with locoregional chest wall recurrences treated with repeat irradiation +/− hyperthermia
Study Patients n= Initial dose (Gy) RT technique Repeat dose (Gy) Complete remission (%) Toxicity grade (%)
Delanian [79] 11 45–65 BT 60 81.8 II/III 45
IV 9
Harms [75] 58 36–70 BT 2 × 20 79.3 III 60b
IV 7
Laramore [69] 13 40–50 EBRT 40–50 61.5 III 0
IV 0
Phromratanapongse [71] 44 35–66 EBRT + HT 16–56 40.9 III 25
IV NR











Kouloulias [81] 15 60 EBRT + HT 30.6 20 III NR
IV 7
Linthorst [73] 198 48 EBRT + HT 8 × 4 78c III/IV 11.9d
Linthorst [78] 248 49 EBRT + HT 8 × 4 39c III 1d
BT brachytherapy, HT hyperthermia, EBRT external beam radiotherapy, NR not reported
aBreast cancer and other tumor entities
bPredominantly telangiectasia
c5-year local control rate
d5-year rate
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Axillary recurrence
The reported cumulative risk of axillary recurrence after 
axillary dissection ranges from 0.5 to 3.0 % [82, 83]. Voogd 
et al. [82] investigated the long-term prognosis of 59 out 
of 4669 patients (1.3 %) with an axillary recurrence after 
axillary dissection. The median interval between treatment 
of the primary tumor and diagnosis of axillary recurrence 
was 2.6 years (range 0.3–10.7 years). Distant metastases 
occurred in 38 of the 59 patients. The 5- and 10-year dis-
tant recurrence-free survival rates were 39 % (95 % confi-
dence interval, CI: 25–52 %) and 29 % (95 % CI: 16–42 %), 
respectively. The authors concluded that axillary recurrence 
following axillary dissection was associated with a high rate 
of subsequent distant metastasis and poor overall progno-
sis, although cure was still achievable in one third of the 
patients. Newman and colleagues [84] reported on 44 out of 
4255 (1 %) breast cancer patients with axillary recurrence. 
With a median follow-up of 70.8 months, complete control 
of axillary recurrence was achieved in 31 patients (71 %). 
Distant metastases developed in 50 % and were more likely 
to occur in the case of uncontrolled axillary recurrences. 
Of the patients receiving multimodality therapy (75 %), the 
most common sequence was surgery followed by either 
systemic therapy and/or nodal irradiation. The addition of 
radiotherapy significantly improved axillary disease control 
(80.8 vs. 55.6 %).
Isolated supraclavicular lymph node recurrence
Van der Sangen et al. [85] investigated 4669 patients treated 
for invasive breast cancer. An isolated supraclavicular 
lymph node recurrence developed in 42 patients (0.9 %). 
Different treatments, including surgery, radiotherapy, sys-
temic therapy, or a combination of these, were applied. 
Complete remission was achieved in 35 patients (83 %). 
However, a second supraclavicular recurrence occurred in 
a third of these patients. Overall, 6 patients (14 %) were 
alive without evidence of disease after a follow-up period of 
4.4–8.3 years. The 5-year actuarial OS and distant disease-
free survival rates were 38 and 22 %, respectively. Distant 
disease-free survival was somewhat better in the 25 patients 
who underwent radiotherapy as part of the treatment for 
supraclavicular recurrence than it was in the 17 patients 
who did not (p = 0.06). The difference reached statisti-
cal significance after the exclusion of 8 patients who had 
received axillary and supraclavicular radiotherapy as part 
of their primary tumor treatment (p = 0.002). In summary, 
complete remission can be obtained in most patients with 
isolated supraclavicular recurrence, although the prognosis 
for these patients is poor.
late toxicity rate amounted to 11.9 % (n = 15 skin ulcerations, 
n = 5 osteoradionecrosis of the ribs). The same working 
group investigated 248 patients with a macroscopic breast 
cancer recurrence treated with reirradiation and hyperther-
mia [78]. After a median follow-up period of 32 months, 
70 % of patients had a complete remission. The 5-year local 
control rate was 39 %. Thermal burn was developed by 23 % 
of patients, which healed with conservative measures. The 
incidence of 5-year late grade 3 toxicity was 1 %.
Conclusions of the DEGRO expert panel for the therapy of 
locoregional recurrences after mastectomy
 ● Multimodality therapy including systemic therapy, sur-
gery, and radiation +/− hyperthermia achieves a high rate 
of local control and can be curative with long-term sur-
vival in a subset of patients.
 ● Patients with an isolated locoregional recurrence after 
mastectomy should undergo surgical resection. Postop-
erative radiation therapy to the chest wall is mandatory 
and regional nodal irradiation (RNI) is strongly advised.
 ● In radiation-naive patients, the chest wall and regional 
lymph nodes should be treated with doses of 50–50.4 Gy 
(1.8–2 Gy per day). A boost dose of 10 Gy may be applied. 
Further dose escalation does not seem to improve treat-
ment results.
 ● In previously irradiated patients with a high risk of a 
second local recurrence after surgical resection or in 
patients with unresectable recurrences, reirradiation 
should be strongly considered. Indication and dose con-
cepts depend on the time interval to first radiotherapy, 
presence of late radiation effects, and concurrent or 
sequential systemic treatment.
 ● In the absence of severe radiogenic stigmata and an 
appropriate time interval (> 1 year), reirradiation with 
doses between 45 and 50 Gy is recommended, but should 
not exceed cumulative doses of 100–110 Gy3 (2-Gy3 
equivalent dose).
 ● Particularly in previously irradiated patients, combi-
nation with hyperthermia can further improve tumor 
control.
Regional recurrences and isolated supraclavicular 
lymph node recurrences
Statement of the German S3 Guidelines 2012 [13]:
Statement recurrence 3: Isolated regional recurrence
a. In case of an isolated regional recurrence, local control 
should be achieved with surgery/radiotherapy.
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Conclusions of the DEGRO expert panel for the treatment 
of axillary or supraclavicular lymph node recurrence
 ● Isolated axillary and supraclavicular recurrences from 
breast cancer are uncommon and may follow any stage 
of disease. Of the affected patients, 50–65 % develop dis-
tant metastases.
 ● To date, only retrospective data concerning the treatment 
of regional nodal recurrence are available.
 ● Durable disease control is best achieved with multimodal-
ity therapy including surgery and radiotherapy. Approxi-
mately one third of patients with an axillary breast cancer 
recurrence can be cured with multimodal therapy.
 ● Radiation therapy significantly improves local control 
and should be applied whenever feasible.
Compliance with ethical guidelines
Conflict of interest W. Harms, W. Budach, J. Dunst, P. Feyer, R. 
Fietkau,·W. Haase, D. Krug, M.D. Piroth, M.-L. Sautter-Bihl, F. Sedl-
mayer, R. Souchon, F. Wenz, and R. Sauer state that there are no con-
flicts of interest.
The accompanying manuscript does not include studies on humans or 
animals.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution License which permits any use, distribution, and 
reproduction in any medium, provided the original author(s) and the 
source are credited.
References
 1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
(2011) Effect of radiotherapy after breast-conserving surgery on 
10-year recurrence and 15-year breast cancer death: meta-analysis 
of individual patient data for 10,801 women in 17 randomised tri-
als. Lancet 378:1707–1716
 2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
(2014) Effect of radiotherapy after mastectomy and axillary sur-
gery on 10-year recurrence and 20-year breast cancer mortality: 
meta-analysis of individual patient data for 8135 women in 22 ran-
domised trials. Lancet 383:2127–2135
 3. Christiansen P, Al Suliman N, Bjerre K, Moller S (2008) Recur-
rence pattern and prognosis in low-risk breast cancer patients–data 
from the DBCG 89-A programme. Acta Oncol 47:691–703
 4. Bartelink H, Maingon P, Poortmans P et al (2015) Whole-breast 
irradiation with or without a boost for patients treated with breast-
conserving surgery for early breast cancer: 20-year follow-up of a 
randomised phase 3 trial. Lancet Oncol 16:47–56
 5. Wahl AO, Rademaker A, Kiel K et al (2008) Multi-institutional 
review of repeat irradiation of chest wall and breast for recurrent 
breast cancer. Int J Radiat Oncol Biol Phys 70:477–484
 6. Nielsen HM, Overgaard M, Grau C et al (2006) Study of failure 
pattern among high-risk breast cancer patients with or without post-
mastectomy radiotherapy in addition to adjuvant systemic therapy: 
long term results from the Danish Breast Cancer Co-operative Group 
DBCG 82b and c randomized studies. J Clin Oncol 24:2268–2275
1 3
207DEGRO practical guidelines for radiotherapy of breast cancer VI
39. Trombetta M, Julian T, Bhandari T et al (2008) Breast conserva-
tion surgery and interstitial brachytherapy in the management of 
locally recurrent carcinoma of the breast: the Allegheny General 
Hospital experience. Brachytherapy 7:29–36
40. Deutsch M (2002) Repeat high-dose external beam irradiation for 
in-breast tumor recurrence after previous lumpectomy and whole 
breast irradiation. Int J Radiat Oncol Biol Phys 53:687–691
41. Kraus-Tiefenbacher U, Bauer L, Scheda A et al (2007) Intraop-
erative radiotherapy (IORT) is an option for patients with local-
ized breast recurrences after previous external-beam radiotherapy. 
BMC Cancer 7:178
42. Guix B, Lejárcegui JA, Tello JI et al (2010) Exeresis and brachy-
therapy as salvage treatment for local recurrence after conserva-
tive treatment for breast cancer: results of a ten-year pilot study. 
Int J Radiat Oncol Biol Phys 78:804–810
43. Kurtz JM, Jacquemier J, Torhorst J et al (1989) Conservation 
therapy for breast cancers other than infiltrating ductal carcinoma. 
Cancer 63:1630–1635
44. Abner AL, Recht A, Eberlein T et al (1993) Prognosis following 
salvage mastectomy for recurrence in the breast after conservative 
surgery and radiation therapy for early-stage breast cancer. J Clin 
Oncol 11:44–48
45. Salvadori B, Marubini E, Miceli R et al (1999) Reoperation for 
locally recurrent breast cancer in patients previously treated with 
conservative surgery. Br J Surg 86:84–87
46. Voogd AC, van Tienhoven G, Peterse HL et al (1999) Local re-
currence after breast conservation therapy for early stage breast 
carcinoma: detection, treatment, and outcome in 266 patients. 
Dutch study group on Local Recurrence after Breast Conservation 
(BORST). Cancer 85:437–446
47. Ishitobi M, Komoike Y, Nakahara S et al (2011) Repeat lumpecto-
my for ipsilateral breast tumor recurrence after breast-conserving 
treatment. Oncology 81:5381–5366
48. Gentilini O, Botteri E, Veronesi P et al (2012) Repeating conserva-
tive surgery after ipsilateral breast tumor reappearance: criteria for 
selecting the best candidates. Ann Surg Oncol 19:3771–3776
49. Sautter-Bihl ML, Sedlmayer F, Budach W, Breast Cancer Expert 
Panel of the German Society of Radiation Oncology (DEGRO) 
et al (2014) DEGRO practical guidelines: radiotherapy of breast 
cancer III–radiotherapy of the lymphatic pathways. Strahlenther 
Onkol 190:342–351
50. Sautter-Bihl ML, Sedlmayer F, Budach W, Breast Cancer Expert 
Panel of the German Society of Radiation Oncology (DEGRO) 
et al (2014) How nescience may obscure evidence. Strahlenther 
Onkol 190:861–863
51. Tendulkar RD, Rehman S, Shukla ME et al (2012) Impact of post-
mastectomy radiation on locoregional recurrence in breast cancer 
patients with 1–3 positive lymph nodes treated with modern sys-
temic therapy. Int J Radiat Oncol Biol Phys 83:577–581
52. Katz A, Strom EA, Buchholz TA et al (2000) Locoregional recur-
rence patterns after mastectomy and doxorubicin-based chemo-
therapy: implications for postoperative irradiation. J Clin Oncol 
18:2817–2827
53. Schwaibold F, Fowble BL, Solin LJ et al (1991) The results of 
radiation therapy for isolated local regional recurrence after mas-
tectomy. Int J Radiat Oncol Biol Phys 21:299–310
54. Stadler B, Kogelnik H (1987) Local control and outcome of pa-
tients irradiated for isolated chest wall recurrences of breast can-
cer. Radiother Oncol 8:105–111
55. Halverson K, Perez C, Kuske R et al (1990) Isolated local-regional 
recurrence of breast cancer following mastectomy: radiotherapeu-
tic management. Int J Radiat Oncol Biol Phys 19:851–858
56. Beck T, Hart N, Woodart D (1983) Local or regionally recurrent 
carcinoma of the breast: results of therapy in 121 patients. J Clin 
Oncol 1:400–405
23. Sautter-Bihl ML, Sedlmayer F, Budach W et al (2012) When are 
breast cancer patients old enough for the quitclaim of local con-
trol? Strahlenther Onkol 188:1069–1073
24. Veronesi U, Marubini E, Del Vecchio M et al (1995) Local re-
currences and distant metastases after conservative breast cancer 
treatments: partly independent events. J Natl Cancer Inst 87:19–27
25. Gujral DM, Sumo G, Owen JR et al (2011) Ipsilateral breast tumor 
relapse: local recurrence versus new primary tumor and the effect 
of whole breast radiotherapy on the rate of new primaries. Int J 
Radiat Oncol Biol Phys 79:19–25
26. Smith TE, Lee D, Turner BC et al (2000) True recurrence vs. new 
primary ipsilateral breast tumor relapse: an analysis of clinical and 
pathologic differences and their implications in natural history, 
prognoses, and therapeutic management. Int J Radiat Oncol Biol 
Phys 48:1281–1289
27. Komoike Y, Akiyama F, Iino Y et al (2005) Analysis of ipsilateral 
breast tumor recurrences after breast-conserving treatment based 
on the classification of true recurrences and new primary tumors. 
Breast Cancer 12:104–111
28. Huang E, Buchholz TA, Meric F et al (2002) Classifying local 
disease recurrences after breast conservation therapy based on lo-
cation and histology: new primary tumors have more favorable out-
comes than true local disease recurrences. Cancer 95:2059–2067
29. Nishimura S, Takahashi K, Akiyama F et al (2005) Classification 
of ipsilateral breast tumor recurrence after breast-conserving ther-
apy: new primary cancer allows a good prognosis. Breast Cancer 
12:112–117
30. Fodor J, Major T, Polgár C et al (2008) Prognosis of patients with 
local recurrence after mastectomy or conservative surgery for 
early stage invasive breast cancer. Breast 17:302–308
31. van Laar C, van der Sangen MJ, Poortmans PM et al (2013) Local 
recurrence following breast-conserving treatment in women aged 
40years or younger: trends in risk and the impact on progno-
sis in a population-based cohort of 1143 patients. Eur J Cancer 
49:3093–3101
32. Miles RC, Gullerud RE, Lohse CM et al (2012) Local recurrence 
after breast-conserving surgery: multivariable analysis of risk fac-
tors and the impact of young age. Ann Surg Oncol 19:1153–1159
33. Alpert TE, Kuerer HM, Arthur DW et al (2005) Ipsilateral breast 
tumor recurrence after breast conservation therapy: outcomes of 
salvage mastectomy vs. salvage breast-conserving surgery and 
prognostic factors for salvage breast preservation. Int J Radiat 
Oncol Biol Phys 63:845–851
34. Sedlmayer F, Zehentmayr F, Fastner G (2013) Partial breast re-
irradiation for local recurrence of breast carcinoma: benefit and 
long term side effects. Breast 22:141–146
35. Hannoun-Levi JM, Resch A, Gal J et al (2013) Accelerated partial 
breast irradiation with interstitial brachytherapy as second conser-
vative treatment for ipsilateral breast tumour recurrence: multi-
centric study of the GEC-ESTRO Breast Cancer Working Group. 
Radiother Oncol 108:226–231
36. Resch A, Fellner C, Mock U et al (2002) Locally recurrent breast 
cancer: pulse dose rate brachytherapy for repeat irradiation follow-
ing lumpectomy–a second chance to preserve the breast. Radiol-
ogy 225:713–718
37. Kauer-Dorner D, Pötter R, Resch A et al (2012) Partial breast ir-
radiation for locally recurrent breast cancer within a second breast 
conserving treatment: alternative to mastectomy? Results from a 
prospective trial. Radiother Oncol 102:96–101
38. Chadha M, Feldman S, Boolbol S et al (2008) The feasibility of 
a second lumpectomy and breast brachytherapy for localized can-
cer in a breast previously treated with lumpectomy and radiation 
therapy for breast cancer. Brachytherapy 7:22–28
1 3
208 W. Harms et al.
72. Van der Zee J, van der Holt B, Rietveld PJM et al (1999) Reirra-
diation combined with hyperthermia in recurrent breast cancer is a 
worthwhile local palliation. Br J Cancer 79:483–490
73. Linthorst M, van Geel AN, Baaijens M et al (2013) Re-irradiation 
and hyperthermia after surgery for recurrent breast cancer. Radio-
ther Oncol 109:188–193
74. Linthorst M, van Geel AN, Baartman EA et al (2013) Effect of 
a combined surgery, re-irradiation and hyperthermia therapy on 
local control rate in radio-induced angiosarcoma of the chest wall. 
Strahlenther Onkol 189:387–393
75. Harms W, Krempien R, Hensley FW et al (2001) Results of chest 
wall re-irradiation using pulsed dose rate (PDR) brachytherapy 
moulds for breast cancer local recurrences. Int J Radiat Oncol Biol 
Phys 49:205–210
76. Amicheti M, Valdagni R, Graiff C, Valentini A (1991) Local-re-
gional recurrences of breast cancer: treatment with radiation thera-
py and local microwave hyperthermia. Am J Clin Oncol 14:60–65
77. Kapp DS, Cox RC (1995) Thermal treatment parameters are most 
predictive of outcome in patients with single tumor nodules per 
treatment field in recurrent adenocarcinoma of the breast. Int J Ra-
diat Oncol Biol Phys 33:887–899
78. Linthorst M, Baaijens M, Wiggenraad R et al (2015) Local control 
rate after the combination of re-irradiation and hyperthermia for 
irresectable recurrent breast cancer: Results in 248 patients. Ra-
diother Oncol 117:217–222
79. Delanian S, Housset M, Brunel P et al (1992) Iridium 192 plesio-
curietherapy using silicone elastomer plates for extensive locally 
recurrent breast cancer following chest wall irradiation. Int J Ra-
diat Oncol Biol Phys 22:1099–1104
80. Li G, Mitsumori M, Ogura M et al (2004) Local hyperthermia 
combined with external irradiation for regional recurrent breast 
carcinoma. Int J Clin Oncol 9:179–183
81. Kouloulias VE, Dardoufas CE, Kouvaris JR et al (2002) Liposo-
mal Doxorubicin in conjunction with re-irradiation and local hy-
perthermia treatment in recurrent breast cancer: a phase I/II trial. 
Clin Cancer Res 8:374–382
82. Voogd AC, Cranenbroek S, de Boer R et al (2005) MJC Long-term 
prognosis of patients with axillary recurrence after axillary dissec-
tion for invasive breast cancer. Eur J Surg Oncol 31:485–489
83. Harris EE, Hwang WT, Seyednejad F, Solin LJ (2003) Prognosis 
after regional lymph node recurrence in patients with stage I–II 
breast carcinoma treated with breast conservation therapy. Cancer 
98:2144–2151
84. Newman LA, Hunt KK, Buchholz T et al (2000) Presentation, 
management and outcome of axillary recurrence from breast can-
cer. Am J Surg 180:252–256
85. Van der Sangen MJC, Coebergh JWW, Roumen RMH et al (2003) 
Detection, treatment, and outcome of isolated supraclavicular re-
currence in 42 patients with invasive breast carcinoma. Cancer 
98:11–17
57. Skinner HD, Strom EA, Motwani SB et al (2013) Radiation dose 
escalation for loco-regional recurrence of breast cancer after mas-
tectomy. Radiat Oncol 8:13
58. Ishitobi M, Matsushita A, Nakayama T et al (2014) Regional lym-
phatic recurrence after salvage surgery for ipsilateral breast tumor 
recurrence of breast cancer without local treatment for regional 
lymphatic basin. J Surg Oncol 110:265–269
59. Vernon CC, Hand JW, Field SB et al (1996) Radiotherapy with 
or without hyperthermia in the treatment of superficial localized 
breast cancer: results from five randomized controlled trials—In-
ternational Collaborative Hyperthermia Group. Int J Radiat Oncol 
Biol Phys 35:731–744
60. Jones EL, Oleson JR, Prosnitz LR et al (2005) Randomized trial 
of hyperthermia and radiation for superficial tumors. J Clin Oncol 
23:3079–3085
61. Borner M, Bacchi M, Goldhirsch A et al (1994) First isolated lo-
coregional recurrence following mastectomy for breast cancer: 
results of a phase III multicenter trial comparing systemic treat-
ment with observation after excision and radiation. J Clin Oncol 
12:2071–2077
62. Aebi S, Gelber S, Anderson SJ (2014) Chemotherapy for Isolated 
Locoregional Recurrence of Breast Cancer: the CALOR Ran-
domised Trial. Lancet Oncol 15:156–163
63. Karasawa K, Katsui K, Seki K et al (2003) Radiotherapy with con-
current docetaxel for advanced and recurrent breast cancer. Breast 
Cancer 10:268–274
64. Semrau S, Gerber B, Reimer T et al (2006) Concurrent radio-
therapy and taxane chemotherapy in patients with locoregional 
recurrence of breast cancer. A retrospective analysis. Strahlenther 
Onkol 182:596–603
65. Zagar TM, Higgins KA, Miles EF et al (2010) Durable palliation 
of breast cancer chest wall recurrence with radiation therapy, hy-
perthermia, and chemotherapy. Radiother Oncol 97:535–540
66. Ballo MT, Strom EA, Prost H et al (1999) Local-regional control 
of recurrent breast carcinoma after mastectomy: does hyperfrac-
tionated accelerated radiotherapy improve local control? Int J Ra-
diat Oncol Biol Phys 44:105–112
67. Willner J, Kiricuta IC, Kölbl O (1997) Locoregional recurrence of 
breast cancer following mastectomy: always a fatal event? Results 
of univariate and multivariate analysis. Int J Radiat Oncol Biol 
Phys 37:853–863
68. Chagpar A, Kuerer HM, Hunt KK et al (2003) Outcome of treat-
ment for breast cancer patients with chest wall recurrence accord-
ing to initial stage: implications for post-mastectomy radiation 
therapy. Int J Radiat Oncol Biol Phys 57:128–135
69. Laramore GE, Griffin TW, Parker RG, Gerdes AJ (1978) The use 
of electron beams in treating local recurrence of breast cancer in 
previously irradiated fields. Cancer 41:991–995
70. Elkort RJ, Kelly W, Mozden PJ, Feldman MI (1980) A combined 
treatment program for the management of locally recurrent breast 
cancer following chest wall irradiation. Cancer 46:647–653
71. Phromratanapongse P, Steeves RA, Severson SB, Paliwal BR 
(1991) Hyperthermia and irradiation for locally recurrent previ-
ously irradiated breast cancer. Strahlenther Onkol 167:93–97
1 3
